Mark Smyth
QIMR Berghofer Medical Research Institute, QLD, Australia
- This delegate is presenting an abstract at this event.

Professor Mark Smyth is a Senior Scientist and Immunology Coordinator at QIMR Berghofer Medical Research Institute. He completed his PhD in 1988 and trained at the NCI (1988-1992), before commencing his independent research career in Australia. Over the last 20 years he rekindled world-wide interest in cancer immune surveillance, defined immune-mediated dormancy of cancer, and the role of the host in chemotherapy and targeted therapy responses in mice and humans. More recently, he has provided new means of classifying natural killer cell (NK) subtypes and two new targets for cancer immunotherapy. He is a past winner of the Coley Medal and Brupbacher Foundation Prizes in Cancer Research. He is the highest cited immunologist in Australia and is a Senior Editor, and Advisory Board Member for Cancer Research and Science, respectively.
Presentations this author is a contributor to:
Efficacy of neoadjuvant immunotherapy is mediated through the selective expansion of tumour-specific CD8+ T cells with a memory precursor phenotype (#30)
2:25 PM
Michele W Teng
Workshop 3: Tumour Immunology
Stem cell transplantation establishes T cell-dependent myeloma immune-equilibrium (#84)
5:30 PM
Simone A Minnie
New Investigator Award Session
The role of atypical chemokine receptor ACKR4 in melanoma anti-tumour immunity (#216)
4:00 PM
Jade Foeng
Poster Session One & Burnet Oration Cocktail Function
IL-18 critically drives multiple myeloma progression by generating an immunosuppressive microenvironment. (#91)
9:00 AM
Mark J Smyth
Plenary III: Cancer Immunology